CA2309557A1 - Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic - Google Patents

Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic Download PDF

Info

Publication number
CA2309557A1
CA2309557A1 CA002309557A CA2309557A CA2309557A1 CA 2309557 A1 CA2309557 A1 CA 2309557A1 CA 002309557 A CA002309557 A CA 002309557A CA 2309557 A CA2309557 A CA 2309557A CA 2309557 A1 CA2309557 A1 CA 2309557A1
Authority
CA
Canada
Prior art keywords
tumor
cells
antigen
trp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002309557A
Other languages
English (en)
Inventor
Andrea Anichini
Giorgio Parmiani
Marialuisa Sensi
Catia Traversari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2309557A1 publication Critical patent/CA2309557A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un antigène polypeptidique spécifique à une tumeur, qui est codé au moins partiellement par un intron d'un antigène tumoral codé par exon . Cet antigène peut être obtenu par (a) par réaction en chaîne de la polymérase de la transcriptase inverse à partir d'ARNm isolé de la fraction cytoplasmique soluble d'une cellule tumorale, et les fragments d'acide nucléique qui s'hybrident dans des conditions sévères avec des séquences d'intron d'un antigène tumoral codé par exon sont utilisés comme sonde. Cet antigène peut également être obtenu par (b) isolation du produit de ladite réaction en chaîne de la polymérase, l'expression dudit produit ainsi obtenu ou d'un fragment de ce dernier dans une cellule hôte, et l'isolation dudit antigène spécifique à une tumeur qui est codé par ledit produit de réaction en chaîne de la polymérase ou un fragment de ce dernier, qui s'hybride également avec des séquences d'exon dudit antigène. Cet antigène présente une grande utilité dans des applications de diagnostic et de thérapie liées à des maladies tumorales.
CA002309557A 1997-11-06 1998-11-02 Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic Abandoned CA2309557A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97119404 1997-11-06
EP97119404.8 1997-11-06
PCT/EP1998/006921 WO1999024566A1 (fr) 1997-11-06 1998-11-02 Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic

Publications (1)

Publication Number Publication Date
CA2309557A1 true CA2309557A1 (fr) 1999-05-20

Family

ID=8227582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002309557A Abandoned CA2309557A1 (fr) 1997-11-06 1998-11-02 Antigenes specifiques a une tumeur, procede de production et utilisation de ces antigenes pour assurer une immunisation et diagnostic

Country Status (11)

Country Link
EP (1) EP1029050A1 (fr)
JP (1) JP2001522603A (fr)
KR (1) KR20010024585A (fr)
CN (1) CN1278865A (fr)
AR (1) AR017562A1 (fr)
AU (1) AU743066B2 (fr)
BR (1) BR9813981A (fr)
CA (1) CA2309557A1 (fr)
TR (1) TR200001253T2 (fr)
WO (1) WO1999024566A1 (fr)
ZA (1) ZA9810130B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
HUE046152T2 (hu) 2011-05-24 2020-02-28 Biontech Rna Pharmaceuticals Gmbh Rák elleni egyedi vakcinák
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
CA2892391C (fr) 2012-11-28 2023-10-17 Biontech Rna Pharmaceuticals Gmbh Vaccins individualises contre le cancer
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
US10564165B2 (en) 2014-09-10 2020-02-18 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
WO2016045732A1 (fr) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Formulations stables de lipides et de liposomes
WO2016128060A1 (fr) 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination
CN107709552B (zh) 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
WO2017059902A1 (fr) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh Séquences utr 3' permettant la stabilisation d'arn
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
CN109069599A (zh) * 2016-03-03 2018-12-21 法国古士塔柏罗斯学院 针对癌症的基于ptp的疫苗
EP3519562A4 (fr) 2016-09-29 2020-03-25 Nantkwest, Inc. Cellules nk-92 déficientes en hla de classe i à immunogénicité réduite
KR102528384B1 (ko) 2017-01-06 2023-05-02 이뮤너티바이오, 인크. 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포
WO2018224166A1 (fr) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Procédés de prédiction de l'utilité de modifications d'acides aminés spécifiques d'une maladie pour l'immunothérapie
EP4576103A3 (fr) * 2017-10-10 2025-08-27 Gritstone bio, Inc. Identification de néoantigènes à l'aide de points chauds
EP3703735A1 (fr) 2017-11-01 2020-09-09 Nantkwest, Inc. Cellules nk-92 pour stimuler un vaccin anticancéreux
WO2019152513A1 (fr) 2018-01-31 2019-08-08 Nantkwest, Inc. Utilisation de 5 % d'albumine humaine dans des milieux de lavage et de récolte
EP3743446A1 (fr) 2018-03-12 2020-12-02 Nantkwest, Inc. Utilisation de cellules nk à haute affinité modifiées par cd33car (t-hank) pour réduire l'activité suppressive de cellules suppressives d'origine myéloïde (ou réduire l'impact négatif sur l'activité des cellules nk)
KR102721140B1 (ko) 2018-05-22 2024-10-24 이뮤너티바이오, 인크. 폴록사머를 사용한 nk-92 세포 성장의 최적화
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
AU2019274392A1 (en) 2018-05-22 2020-11-05 Nantkwest, Inc. Basal media for growing NK-92 cells
WO2020014245A1 (fr) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryoconservation
KR102778139B1 (ko) 2018-07-10 2025-03-10 이뮤너티바이오, 인크. 제대혈로부터 cik nkt 세포의 생성
IL314189A (en) 2018-08-01 2024-09-01 Immunitybio Inc A QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR OR A CYTOKINE, AND CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES- Expedited Examination
EP3830113A1 (fr) 2018-08-01 2021-06-09 Nantkwest, Inc. Cellules tueuses naturelles activées sensibles aux chimiokines à activation secondaire d'écotropisme pour cibles vérifiées
US12498363B2 (en) 2018-08-01 2025-12-16 Immunitybio, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
EP3743513A4 (fr) 2018-11-06 2021-11-24 Nantkwest, Inc. Cellules nk-92 modifiées par un récepteur antigénique chimérique
US20220017594A1 (en) 2018-11-26 2022-01-20 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
CN110491450B (zh) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 肿瘤新生抗原预测平台及其应用
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2023081163A1 (fr) 2021-11-02 2023-05-11 Immunitybio, Inc. Cellules tueuses naturelles pour une thérapie contre les chordomes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
BR9813981A (pt) 2000-09-26
EP1029050A1 (fr) 2000-08-23
JP2001522603A (ja) 2001-11-20
CN1278865A (zh) 2001-01-03
TR200001253T2 (tr) 2000-11-21
AR017562A1 (es) 2001-09-12
KR20010024585A (ko) 2001-03-26
WO1999024566A1 (fr) 1999-05-20
AU743066B2 (en) 2002-01-17
AU2151899A (en) 1999-05-31
ZA9810130B (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU743066B2 (en) Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
Lupetti et al. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
Boël et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
Wang et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
JP3496071B2 (ja) 腫瘍拒絶抗原前駆体ｄａｇｅをコードする単離核酸分子とその利用方法
US5821122A (en) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US5831016A (en) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
KR100380503B1 (ko) 흑색종관련항원성폴리펩티드,그에피토프및흑색종에대한백신
RU2234942C2 (ru) Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US20070031432A1 (en) Tumor antigen
JP2002520054A (ja) 前立腺癌の治療及び診断のための組成物及び方法
CA2304167A1 (fr) La mammaglobine, proteine secretee du cancer du sein specifique de la glande mammaire
JPH09504165A (ja) Ｇａｇｅ腫瘍拒絶抗原前駆体の発現を決定する事による疾患診断法
US5843648A (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
JP2001516226A (ja) 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
JP2009511424A (ja) メラノーマ関連ｍｈｃクラスｉ関連オリゴペプチドおよびその使用
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
KR20020026418A (ko) 유방암을 치료 및 진단하기 위한 조성물 및 방법
US20020111467A1 (en) Compositions and methods for the treatment and diagnosis of breast cancer
MXPA00004307A (en) Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
US20090311279A1 (en) Colorectal Cancer Antigen
AU697527B2 (en) Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof
US7270980B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
Visser et al. Molecular characterization of melanoma-derived antigens
CA2506684A1 (fr) Epitopes immunogenes pour facteur de croissance fibroplastique 5 (fgf-5) presente par hla-a3 et hla-a2

Legal Events

Date Code Title Description
FZDE Dead